Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

European Journal of Cancer

Volumn 44, Issue 12, 2008, Pages 1734-1743

  Shimazaki, Naomi ^a   Togashi, Noriko ^a   Hanai, Masaharu ^a   Isoyama, Takeshi ^a   Wada, Kunio ^a   Fujita, Takashi ^a   Fujiwara, Kosaku ^a   Kurakata, Shinichi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cytostatic; Peroxisome proliferator activated receptor gamma; Thiazolidinedione

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ADIPONECTIN; CS 7017; DRUG VEHICLE; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMID VECTOR; ROSIGLITAZONE;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MICE; MICE, NUDE; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48349144845     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.04.016     Document Type: Article

References (29)

1. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
2. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 (1995) 803-812
3. Kliewer S.A., Sundseth S.S., Jones S.A., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor α and γ. Proc Natl Acad Sci USA 94 (1997) 4318-4323
4. Lehmann J.M., Moore L.B., Smith-Oliver T.A., et al. Anantidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270 (1995) 12953-12956
5. Tontonoz P., Singer S., Forman B.M., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 94 (1997) 237-241
6. Kletzien R.F., Foellmi L.A., Harris P.K., et al. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 42 (1992) 558-562
7. Maeda N., Takahashi M., Funahashi T., et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
8. Cowherd R.M., Lyle R.E., and McGehee Jr. R.E. Molecular regulation of adipocyte differentiation. Semin Cell Dev Biol 10 (1999) 3-10
9. Dwight T., Thoppe S.R., Foukakis T., et al. Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumours. J Clin Endocrinol Metab 88 (2003) 4440-4445
10. Sarraf P., Mueller E., Smith W.M., et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 3 (1999) 799-804
11. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 5 (2004) 419-429
12. Mueller E., Sarraf P., Tontonoz P., et al. Terminal differentiation of human breast cancer through PPARγ. Molec Cell 1 (1998) 465-470
13. Demetri G.D., Fletcher C.D.M., Mueller E., et al. Induction of solid tumour differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96 (1999) 3951-3956
14. Hisatake J., Ikezoe T., Carey M., et al. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res 60 (2000) 5494-5498
15. Kulke M.H., Demetri G.D., Sharpless N.E., et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8 (2002) 395-399
16. Fenner M.H., and Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs 14 (2005) 557-568
17. Copland J.A., Marlow L.A., Kurakata S., et al. Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumour growth via p21WAF1/CIP1. Oncogene 25 (2006) 2304-2317
18. Holbeck S.L. Update on NCI in vitro drug screen utilities. Eur J Cancer 40 (2004) 785-793
19. Fajas L., Auboeuf D., Raspe E., et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272 (1997) 18779-18789
20. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endoclinol Metab 86 (2001) 1930-1935
21. Natesan S., Rivera V.M., Molinari E., et al. Transcriptional squelching re-examined. Nature 390 (1997) 349-350
22. Hu E., Kim J.B., Sarraf P., and Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274 (1996) 2100-2103
23. Warrell Jr. R.P. Applications for retinoids in cancer therapy. Semin Hematol 31 (1994) 1-13
24. Shimada T., Kojima K., Yoshiura K., et al. Characteristics of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658-664
25. Konopleva M., Elstner E., McQueen T.J., et al. Peroxisome proliferator-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 10 (2004) 1249-1262
26. Weng J.R., Chen C.Y., Pinzone J.J., et al. Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumour effect of thiazolidinediones. Endocr-Relat Cancer 13 (2006) 401-413
27. Jiang C., Ting A.T., and Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
28. Xin X., Yang S., Kowakski J., et al. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274 (1999) 9116-9121
29. Panigrahy D., Singer S., Shen L.Q., et al. PPARγ ligands inhibit primary tumour growth and metastasis by inhibiting angiogenesis. J Clin Invest 110 (2002) 923-932